Disease activity assessment in patients with psoriatic arthritis
Author:
Publisher
Elsevier BV
Subject
Rheumatology
Reference83 articles.
1. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis;Scotti;Semin Arthritis Rheum,2018
2. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
3. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis;Griffiths;N Engl J Med,2010
4. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial;McInnes;Ann Rheum Dis,2014
5. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study;Papp;Br J Dermatol,2013
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Barriers and facilitators to application of treat-to-target management in psoriatic arthritis and axial spondyloarthritis in practice: A systematic literature review;Seminars in Arthritis and Rheumatism;2024-12
2. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies;Seminars in Arthritis and Rheumatism;2023-02
3. Cardiovascular Safety in the Treatment of Chronic Rheumatic Pathologies;International Journal of Pharmaceutical Research and Allied Sciences;2023
4. The role of IL‐23 and the use of IL‐23 inhibitors in psoriatic arthritis;Musculoskeletal Care;2022-09-07
5. Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis;RMD Open;2022-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3